Spots Global Cancer Trial Database for Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
Official Title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients With Advanced Solid Malignancies
Study ID: NCT01213160
Interventions
Study Description
Brief Summary: The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.
Detailed Description: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies.
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Chuo-ku, , Japan
Research Site, Nagoya-shi, , Japan
Research Site, Sapporo-shi, , Japan
Contact Details
Name: Paul Stockman
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Hideo Saka, MD, PhD
Affiliation: National Hospital Organisation Nagoya Medical Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Yasuo Takahashi, MD
Affiliation: National Hospital OrganisationHokkaido Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
